2015 Canadian Cancer Research Conference
Exploring the Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Cancer Treatment
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Dianhydrogalactitol (VAL-083) enhances activity of platinum drugs in non-small cell lung cancer
American Association for Cancer Research (AACR) Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Conference
A comparison of mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to cisplatin in ovarian tumor models harbouring wild-type and mutant p53
16th World Conference on Lung Cancer, Denver, Colorado
Tuesday, September 8, 2015 poster session. Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain
Tuesday, September 8, 2015 poster session. Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma
ASCO Annual Meeting, Chicago, Illinois
Monday, June 1, 2015 poster session. Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma Multiforme (GBM)
106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania
Monday, April 20, 2015 poster session: VAL-083 Phase 1/2 data poster # CT217: Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma
106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania
Monday, April 20, 2015 poster session: VAL-083 GBM preclinical poster #2562: Dianhydrogalactitol inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo
106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania
Sunday, April 19, 2015 poster session: VAL-083 NSCLC preclinical poster # 751: In vitro activity of dianhydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer